Navigation Links
Strategy to help doctors determine when to treat retinopathy of prematurity
Date:4/29/2010

NEW YORK (April 29, 2010) -- Scientists have shown that through eye examinations, doctors can identify infants who are most likely to benefit from early treatment for a potentially blinding eye condition called retinopathy of prematurity (ROP), resulting in better vision for many children.

These long-term results of the Early Treatment for Retinopathy of Prematurity (ETROP) study confirm that the visual benefit of early treatment for selected infants continues through six years of age. The research is published in the April 12 online issue of Archives of Ophthalmology and was supported by the National Eye Institute (NEI), part of the National Institutes of Health. The Edward S. Harkness Eye Institute at NewYork-Presbyterian Hospital/Columbia University Medical Center and NewYork-Presbyterian/Morgan Stanley Children's Hospital were among the 26 participating study sites.

"We showed that early treatment for high-risk premature babies can improve their vision. This research promises to transform the way babies with ROP are treated," says Dr. John Flynn, study principal investigator and the Anne S. Cohen Professor of Clinical Pediatric Ophthalmology at Columbia University College of Physicians and Surgeons and an ophthalmologist at NewYork-Presbyterian/Morgan Stanley Children's Hospital and professor of medicine at Weill Cornell Medical College.

"We showed there isn't a single treatment strategy that works for all infants with ROP, but rather that doctors need to determine whether the baby has a mild or severe form of the disease before proceeding with retinal surgery," adds study co-author Dr. Michael Chiang, associate professor of ophthalmology at Columbia University College of Physicians and Surgeons and an ophthalmologist at NewYork-Presbyterian Hospital/Columbia University Medical Center. "This can be determined with a simple bedside exam using an ophthalmoscope to look at blood vessels in the retina."

An estimated 15,000
'/>"/>

Contact: Belinda Mager
bem9048@nyp.org
212-305-5587
New York- Presbyterian Hospital/Columbia University Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. A Nutty Super Bowl Snacks Strategy Helps Keep Diets in Play
2. Medical Breakthrough: Drug Free Strategy Shows Promise for Reversing or Halting Osteoporosis for Michigan Men and Women
3. Health Reform Needs Enforceable National Workforce Strategy
4. Research highlights need for national HIV strategy
5. Governor Rendell Proposes Budget With No Tax Increase, More Money for Public Schools, Strategy for Jobs, Plan to Address Future Deficits
6. SOKO Fitness & Spa Group Broadens Geographic Expansion Strategy
7. Keenan Chief Strategy Officer Selected to Join Editorial Board of Payers & Providers
8. Data Strategy Announces SurePath Services Offering for EMC Avamar
9. New strategy produces promising advance in cancer vaccines
10. New Cancer-Fighting Strategy Focuses On Signaling Molecules
11. Targeting leukemia cells gene addiction presents new strategy for treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, ... common antidepressant can quickly alter the way brain cells communicate ... online Sept. 18 in Current Biology , are ... prescribed antidepressants. Experts said the hope is to eventually be ... benefit from a drug -- and which people would fare ...
(Date:9/18/2014)... true: exercise is good for you. But new research ... have an added benefit for cancer patients undergoing chemotherapy. ... melanoma, found that combining exercise with chemotherapy shrunk tumors ... associate professor in the School of Nursing and director ... was the senior author on the study, which appears ...
(Date:9/18/2014)... Texas (PRWEB) September 19, 2014 ... Inside the Neighborhood Mission (Misión Barrio Adentro), ... of the healthcare system (see Section 6.1.3.). ... billion) in an Autonomous Service of Pharmaceutical ... production plant, which provides medicines at a ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Thousands of ... be recognizing their shared fundraising impact on 127 member ... 25. , The first-ever Dance Marathon Day will officially ... million projected to be raised by college and high ... Hospital. Donations generated through Dance Marathon campus programs help ...
(Date:9/18/2014)... 18, 2014 Ben Quirk, CEO of ... Jr. Leadership Award by the Savannah Science Seminar in ... wellness throughout the nation and especially in Savannah. , ... said Ben. “The Savannah Science Seminar is an amazing ... multiple generations have gone through the program,” he added. ...
Breaking Medicine News(10 mins):Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2
... arms to snip away tumors , TUESDAY, Dec. 18 ... promise in the removal of cancer involving the tonsils, ... University of Pennsylvania, the transoral robotic surgery (TORS) system ... with an endoscope, an optical instrument with two video ...
... in the December issue of The Journal of the ... cancer operations in 80-year-olds are considerably worse than reported ... lead to unrealistic expectations about the safety of these ... patients and their physicians may have difficulty accurately assessing ...
... Calif., Dec. 18 BioMarin,Pharmaceutical Inc. (Nasdaq and ... Canadian rights for tetrahydrobiopterin (BH4), including,Kuvan(TM) (sapropterin dihydrochloride), ... Germany. Kuvan is an oral small molecule for ... Merck,Serono. Based on published literature, there are approximately ...
... 18 Art Mellor is one of,more than 400,000 ... from,Multiple Sclerosis (MS). It,s, a debilitating disease that causes,paralysis, ... no wonder that Mellor, the founder of the Accelerated,Cure ... and more,interested in raising the funds he needs to ...
... Southwestern Medical Center researchers have found that the existing body ... of obese patients at risk of cardiovascular disease. , ... Surgery for Obesity and Related Diseases, is among ... index (BMI) and cardiovascular disease as it relates to bariatric ...
... and Implantability Characteristics, MINNEAPOLIS, Dec. 18 ... manufacturer and marketer of state-of-the-art cardiac,surgery products ... Drug,Administration (FDA) approval for the ATS Open ... http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ), The ATS AP360 heart ...
Cached Medicine News:Health News:Robotic Surgery Treats Tonsil Cancer 2Health News:Study finds outcomes of high-risk cancer operations in 80-year-olds worse than reported 2Health News:BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono 2Health News:BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono 3Health News:BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono 4Health News:This Holiday Season Some Dream of a White Christmas - The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 2Health News:This Holiday Season Some Dream of a White Christmas - The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 3Health News:BMI criteria for obesity surgery should be lowered, UT Southwestern researchers suggest 2Health News:ATS Medical Receives FDA Approval for AP360 Mechanical Heart Valve 2Health News:ATS Medical Receives FDA Approval for AP360 Mechanical Heart Valve 3
(Date:9/18/2014)... Australia , Sept. 18, 2014 Veterinary ... of Dr. Ashraf Hanna , M.D., Ph.D., and ... Board of Directors. Dr. Hanna is the Vice President ... Chief Financial Officer for the Genentech Foundation, while Dr. ... Head of Business Development and Licensing for Roche Pharma. ...
(Date:9/18/2014)... 18, 2014  Spring Bank Pharmaceuticals, Inc., a ... treatment of RNA viruses, today announced a research ... for animal testing of the Company,s lead compound, ... "Special Pathogens," against which currently there are no ... Spring Bank,s proprietary Small Molecule Nucleic Acid ...
(Date:9/18/2014)...   Auxilium Pharmaceuticals, Inc. (NASDAQ: ... announced the first presentation of positive safety and ... Investigation of Collagenase Optimizing the Resolution of Dupuytrens) ... histolyticum (CCH) for the treatment of two Dupuytren,s ... the study examined expanded flexibility with timing of ...
Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 2Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 3Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 4Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 5Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 6Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 7
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
... Cobalt Binding (ACB®) Test is a clinical ... (IMA®) by measuring the cobalt binding capacity ... First identified in the early 1990s, IMA ... contact with ischemic tissue in the heart. ...
Inquire...
Medicine Products: